Trials / Withdrawn

WithdrawnNCT06254742

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Study on Preference and Safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Status: Withdrawn
Phase: Phase 3
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.

Conditions

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

Interventions

Type	Name	Description
DRUG	HHPG-19K Injection	first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection

Timeline

Start date: 2024-02-01
Primary completion: 2025-07-01
Completion: 2025-07-01
First posted: 2024-02-12
Last updated: 2025-08-07

Source: ClinicalTrials.gov record NCT06254742. Inclusion in this directory is not an endorsement.